Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb biomarker discovery trial of carboplatin + cyclophosphamide versus paclitaxel with or without atezolizumab in advanced triple-negative breast cancer
2013-001484-23Phase 2Active
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Apr 2013
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, paclitaxel, carboplatin and cyclophosphamide in triple-negative breast cancer (TNBC) and breast cancer (4 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: BRCA-like biomarker prediction of differential progression-free survival. Started Apr 2013; status: active.
02
Drugs
atezolizumabpaclitaxelcarboplatincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2013-001484-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001484-23.